Jade Biosciences Announces Proposed Underwritten Public Offering
Jade Biosciences, a clinical-stage biotechnology company focused on autoimmune therapies, announced its intent to offer shares of common stock and pre-funded warrants in a proposed underwritten public offering. Proceeds, together with existing cash, will be used to fund clinical trials, preclinical studies, manufacturing, research and development, …